Hemant Surgical Industries Ltd (HSIL) — shareholding pattern, promoter holding, financials and share price
About Hemant Surgical Industries Ltd (HSIL)
Hemant Surgical Industries Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as HSIL and on the BSE under scrip code 543916. Its ISIN is INE0GYI01028.
Incorporated in 1989, Hemant Surgical Industries Ltd is in the business of Medical Equipment & Supplies [1]
Hemant Surgical Industries Limited specializes in medical equipment and supplies, focusing on renal care, cardiovascular disease, and other critical care products.
The company evolved from importing medical disposables to manufacturing a wide range of medical devices and solutions in India.
Listed peers in Medical Equipment & Supplies: OSEL Devices Ltd, Fabtech Technologies Ltd, Vasa Denticity Ltd, Prevest Denpro Ltd, Yash Optics & Lens Ltd, Aprameya Engineering Ltd.
Valuation & Returns
10 Jul 2026At ₹369.6 a share on 10 Jul 2026, Hemant Surgical Industries Ltd (HSIL) was valued at a price-to-earnings ratio of 29.54x against an industry P/E of 44.11x and a price-to-book of 3.21x on a book value of ₹115 per share. Solomo computes return on equity of 13.22% and return on capital employed of 14.71% from filed results.
- P/E
- 29.54x
- Industry P/E
- 44.11x
- P/B
- 3.21x
- EPS (TTM)
- ₹12.51
- Book value / share
- ₹115
- ROE
- 13.22%
- ROCE
- 14.71%
- ROA
- 6.63%
- Debt / equity
- 0.36x
- Dividend yield
- 0%
- EBITDA margin
- 12.55%
- 52-week range
- ₹120.64 – ₹446
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Hemant Surgical Industries Ltd (HSIL) reported revenue of ₹232 crore, net profit of ₹18 crore and earnings per share of ₹13.95. That compares with revenue of ₹107 crore and net profit of ₹8 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹167 crore and net profit ₹13 crore (consolidated).
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue (₹ cr) | 107 | 232 |
| Net profit (₹ cr) | 8 | 18 |
| EPS (₹) | 7.7 | 13.95 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 13.63% | 0.94% | 0.87% |
| Profit growth | 74.58% | 20.79% | -17.04% |
| Stock price CAGR | - | 24% | 107% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 58.9% of Hemant Surgical Industries Ltd (HSIL), foreign institutional investors (FII) hold 0.15% and domestic institutional investors (DII) hold 10.73%. Market capitalisation was ₹537 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2023.
Largest disclosed public shareholders in Mar 2026: SINGULARITY LARGE VALUE FUND I 3.83%, WEALTHWAVE CAPITAL TRUST-WEALTHWAVE CAPITAL FUND 3.07%, MONA LAROIA 2.57%, RENU DEVI HISARIA 2.3%, SWATI POKHARNA 2.3%, SINGULARITY EQUITY FUND I 1.91%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 58.9% | - | 0.15% | 10.73% | 41.1% |
| Sep 2025 | 58.9% | - | 0.15% | 10.81% | 41.1% |
| Mar 2025 | 73.56% | - | 0.39% | 1.11% | 26.44% |
| Sep 2024 | 73.56% | - | - | 1.13% | 26.44% |
| Mar 2024 | 73.56% | - | - | 1.97% | 26.44% |
| Sep 2023 | 73.56% | - | 0.03% | 4.26% | 26.44% |